Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 19502066)

1.

Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose.

Ko H, Das A, Carter RL, Fricks IP, Zhou Y, Ivanov AA, Melman A, Joshi BV, Kovác P, Hajduch J, Kirk KL, Harden TK, Jacobson KA.

Bioorg Med Chem. 2009 Jul 15;17(14):5298-311. doi: 10.1016/j.bmc.2009.05.024. Epub 2009 May 15.

2.

Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups.

Das A, Ko H, Burianek LE, Barrett MO, Harden TK, Jacobson KA.

J Med Chem. 2010 Jan 14;53(1):471-80. doi: 10.1021/jm901432g.

3.

Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists.

Ko H, Carter RL, Cosyn L, Petrelli R, de Castro S, Besada P, Zhou Y, Cappellacci L, Franchetti P, Grifantini M, Van Calenbergh S, Harden TK, Jacobson KA.

Bioorg Med Chem. 2008 Jun 15;16(12):6319-32. doi: 10.1016/j.bmc.2008.05.013. Epub 2008 May 9.

4.

Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor.

Ko H, Fricks I, Ivanov AA, Harden TK, Jacobson KA.

J Med Chem. 2007 May 3;50(9):2030-9. Epub 2007 Apr 4.

5.

Enhanced potency of nucleotide-dendrimer conjugates as agonists of the P2Y14 receptor: multivalent effect in G protein-coupled receptor recognition.

Das A, Zhou Y, Ivanov AA, Carter RL, Harden TK, Jacobson KA.

Bioconjug Chem. 2009 Aug 19;20(8):1650-9. doi: 10.1021/bc900206g. Epub 2009 Jul 2.

6.

Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y(4) receptor.

Maruoka H, Jayasekara MP, Barrett MO, Franklin DA, de Castro S, Kim N, Costanzi S, Harden TK, Jacobson KA.

J Med Chem. 2011 Jun 23;54(12):4018-33. doi: 10.1021/jm101591j. Epub 2011 May 20.

7.

Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands.

Nandanan E, Jang SY, Moro S, Kim HO, Siddiqui MA, Russ P, Marquez VE, Busson R, Herdewijn P, Harden TK, Boyer JL, Jacobson KA.

J Med Chem. 2000 Mar 9;43(5):829-42.

PMID:
10715151
8.

Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists.

Ravi RG, Kim HS, Servos J, Zimmermann H, Lee K, Maddileti S, Boyer JL, Harden TK, Jacobson KA.

J Med Chem. 2002 May 9;45(10):2090-100.

PMID:
11985476
9.

Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.

Maruoka H, Barrett MO, Ko H, Tosh DK, Melman A, Burianek LE, Balasubramanian R, Berk B, Costanzi S, Harden TK, Jacobson KA.

J Med Chem. 2010 Jun 10;53(11):4488-501. doi: 10.1021/jm100287t.

10.

5-OMe-uridine-5'-O-(α-boranodiphosphate), a novel nucleotide derivative highly active at the human P2Y(6) receptor protects against death-receptor mediated glial apoptosis.

Haas M, Ginsburg-Shmuel T, Fischer B, Reiser G.

Neurosci Lett. 2014 Aug 22;578:80-4. doi: 10.1016/j.neulet.2014.06.030. Epub 2014 Jun 23.

PMID:
24970757
11.

Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5'-triphosphate analogues at the human P2Y2 and P2Y4 receptors.

Jacobson KA, Costanzi S, Ivanov AA, Tchilibon S, Besada P, Gao ZG, Maddileti S, Harden TK.

Biochem Pharmacol. 2006 Feb 14;71(4):540-9. Epub 2005 Dec 15.

12.

Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors.

Kim HS, Ravi RG, Marquez VE, Maddileti S, Wihlborg AK, Erlinge D, Malmsjö M, Boyer JL, Harden TK, Jacobson KA.

J Med Chem. 2002 Jan 3;45(1):208-18.

PMID:
11754592
13.

Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor.

Besada P, Shin DH, Costanzi S, Ko H, Mathé C, Gagneron J, Gosselin G, Maddileti S, Harden TK, Jacobson KA.

J Med Chem. 2006 Sep 7;49(18):5532-43.

14.

Molecular recognition at purine and pyrimidine nucleotide (P2) receptors.

Jacobson KA, Costanzi S, Ohno M, Joshi BV, Besada P, Xu B, Tchilibon S.

Curr Top Med Chem. 2004;4(8):805-19. Review.

PMID:
15078212
15.

UDP-glucose acting at P2Y14 receptors is a mediator of mast cell degranulation.

Gao ZG, Ding Y, Jacobson KA.

Biochem Pharmacol. 2010 Mar 15;79(6):873-9. doi: 10.1016/j.bcp.2009.10.024. Epub 2009 Nov 5.

16.

Shift in purine/pyrimidine base recognition upon exchanging extracellular domains in P2Y 1/6 chimeric receptors.

Hoffmann C, Soltysiak K, West PL, Jacobson KA.

Biochem Pharmacol. 2004 Nov 15;68(10):2075-86.

17.

UDP is a competitive antagonist at the human P2Y14 receptor.

Fricks IP, Maddileti S, Carter RL, Lazarowski ER, Nicholas RA, Jacobson KA, Harden TK.

J Pharmacol Exp Ther. 2008 May;325(2):588-94. doi: 10.1124/jpet.108.136309. Epub 2008 Feb 5.

18.

Nucleotide analogues containing 2-oxa-bicyclo[2.2.1]heptane and l-alpha-threofuranosyl ring systems: interactions with P2Y receptors.

Ohno M, Costanzi S, Kim HS, Kempeneers V, Vastmans K, Herdewijn P, Maddileti S, Gao ZG, Harden TK, Jacobson KA.

Bioorg Med Chem. 2004 Nov 1;12(21):5619-30.

19.

Synthesis and P2Y receptor activity of nucleoside 5'-phosphonate derivatives.

Cosyn L, Van Calenbergh S, Joshi BV, Ko H, Carter RL, Kendall Harden T, Jacobson KA.

Bioorg Med Chem Lett. 2009 Jun 1;19(11):3002-5. doi: 10.1016/j.bmcl.2009.04.027. Epub 2009 Apr 14.

20.

2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists.

Kim HS, Ohno M, Xu B, Kim HO, Choi Y, Ji XD, Maddileti S, Marquez VE, Harden TK, Jacobson KA.

J Med Chem. 2003 Nov 6;46(23):4974-87.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk